CO5640143A2 - Formulaciones parenterales de un peptido para el tratamiento de lupus eritematoso sistematico - Google Patents

Formulaciones parenterales de un peptido para el tratamiento de lupus eritematoso sistematico

Info

Publication number
CO5640143A2
CO5640143A2 CO05079328A CO05079328A CO5640143A2 CO 5640143 A2 CO5640143 A2 CO 5640143A2 CO 05079328 A CO05079328 A CO 05079328A CO 05079328 A CO05079328 A CO 05079328A CO 5640143 A2 CO5640143 A2 CO 5640143A2
Authority
CO
Colombia
Prior art keywords
ala
glu
lys
ser
gly
Prior art date
Application number
CO05079328A
Other languages
English (en)
Inventor
Vered Sharon Cohen
Esmira Naftali
Vera Weinstein
Adrian Gilbert
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of CO5640143A2 publication Critical patent/CO5640143A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

1.- Una composición farmacéutica, que comprende:un vehículo acuoso; desde 0.1 mg/ml a 20 mg/ml de la composición de una sal farmacéuticamente aceptable de a) un péptido que comprende por lo menos 12 y por lo menos 30 aminoácidos consecutivos que tienen una secuencia correspondiente a (i) una secuencia de aminoácidos encontrada dentro de una región que determina la capacidad de complementación (CDR) de una cadena ligera o pesada de un anticuerpo ID 16/6 anti-ADN monoclonal humano o (ii) una secuencia de aminoácidos encontrada dentro de una región que determina la capacidad de complementación (CDR) de una cadena ligera o pesada de un anticuerpo monoclonal anti-ADN patogénico que induce una respuesta similar al lupus sistémico eritematoso (SLE) en ratones, o b) un péptido que comprende aminoácidos consecutivos que tienen la secuencia (i) TGYYX1X2X3X4X5QSPEKSLEWIG (SEQ ID NO: 11), caracterizado porque X1 es Met, Ala o Val; X2 es Gln, Asp, Glu o Arg: X3 es Trp o Ala; X4 es Val o Ser; y X5 es Lys, Glu o Ala; (ii) EINPSTGGX6X7X8X9X10X11X12KAKAT (SEQ ID NO: 12), caracterizado porque X6 y X7, cada una son Thr, Val o Ara; X8 es Tyr o Phe; X9 es Asn o Asp; X10 es Gln o Glu; X11 es Lys o Glu; yX12 es Phe o Tyr; (iii) YYCARX13X14X15X16PYAX17X18YWGQGS (SEQ ID NO: 13), caracterizada porque X13 es Phe, Thr o Gly; X14 es Leu, Ala o Ser; X15 es Trp o Ala; X16 es Glu o Lys; X17 es Met o Ala; y X18 es Asp, Lys o Ser; (iv) GYNX19X20X21X22X23X24SHGX25X26LEWIG (SEQ ID NO: 14), caracterizada porque X19 es Met o Ala; X20 es Asn, Ap o Arg; X21 es Trp o Ala; X22 es Val o Ser; X23 es Lys o Glu; X24 es Gln o Ala; X25 es Lys o Glu; y X26 es Ser o Ala; (v) YYCARX27X28X29X30X31X32GQTL (SEQ ID NO: 15) , caracterizada porque X27 es Ser o Phe; X28 es Gly o Ala; X29 es Arg, Ala o Glu; X30 es Asn o Asp; X31 es Tyr o Phe, y X32 es Trp, His o Ala; (vi) X33YYWSWIX34QX35PX36X37GX38EWIG (SEQ ID NO: 16),caracterizada porque X33 es Gly o Thr Gly; X34 es Arg o Lys; X35 es Pro o Ser; X36 es Gly o Glu; X37 es Lys o Asp; y X38 es Glu, Leu o Ser; (vii) YYCARX39LLX40X41X42X43X44DVDYX45GX46DV (SEQ ID NO: 17), caracterizada porque X39 es Gly o Phe, X40 es Arg o Ala; X41 es Gly o Ala; X42 es Gly o Ala; X43 es Trp o Ala; X44 es Asn o Ala; X45 es Tyr o Trp; X46 es Met o Gin; ...
CO05079328A 2003-01-14 2005-08-10 Formulaciones parenterales de un peptido para el tratamiento de lupus eritematoso sistematico CO5640143A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43991803P 2003-01-14 2003-01-14

Publications (1)

Publication Number Publication Date
CO5640143A2 true CO5640143A2 (es) 2006-05-31

Family

ID=32771757

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05079328A CO5640143A2 (es) 2003-01-14 2005-08-10 Formulaciones parenterales de un peptido para el tratamiento de lupus eritematoso sistematico

Country Status (21)

Country Link
US (3) US20050008634A1 (es)
EP (1) EP1594434B1 (es)
JP (2) JP4817068B2 (es)
KR (1) KR20050100617A (es)
CN (1) CN1774259B (es)
AU (1) AU2004206842A1 (es)
BR (1) BRPI0406745A (es)
CA (1) CA2513320C (es)
CO (1) CO5640143A2 (es)
CR (1) CR7938A (es)
DK (1) DK1594434T3 (es)
EA (1) EA009123B1 (es)
EC (1) ECSP055961A (es)
ES (1) ES2606464T3 (es)
IL (1) IL169574A (es)
IS (1) IS7972A (es)
MX (1) MXPA05007549A (es)
NO (1) NO20053773L (es)
NZ (1) NZ541658A (es)
WO (1) WO2004064787A2 (es)
ZA (1) ZA200506206B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
DK1594434T3 (da) * 2003-01-14 2017-01-02 Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus
CA2513331A1 (en) * 2003-01-14 2004-08-05 Teva Pharmaceutical Industries Ltd Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CN102281903B (zh) * 2008-11-17 2013-11-13 弗·哈夫曼-拉罗切有限公司 降低大分子在生理条件下聚集的方法和配方
PL3702374T3 (pl) 2012-02-15 2022-11-21 Cydex Pharmaceuticals, Inc. Sposób wytwarzania pochodnych cyklodekstryny
MA37753B1 (fr) * 2012-07-12 2019-04-30 Sanofi Sa Composition antitumorale comprenant le composé 1-(6-{[6-(4-fluorophényl)[1,2,4]triazolo[4,3-b] pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-yléthyl)urée
KR102112119B1 (ko) 2012-10-22 2020-05-19 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
WO2014193611A1 (en) * 2013-05-29 2014-12-04 Oklahoma Medical Research Foundation Bright/arid3a function/expression as a marker for systemic lupus erythematosus severity and intensity
US10189881B2 (en) 2013-07-26 2019-01-29 The Regents Of The University Of California MPS peptides and use thereof
US10314889B2 (en) * 2013-12-20 2019-06-11 The Regents Of The University Of California Suppression of allergic lung inflammation and hyperreactivity
US10851184B2 (en) 2014-08-22 2020-12-01 Cydex Pharmaceuticals, Inc. Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
KR20180098625A (ko) 2015-12-30 2018-09-04 제넨테크, 인크. 분해가 감소된 폴리소르베이트를 갖는 제형
TWI797073B (zh) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
AU2018205885A1 (en) 2017-01-05 2019-06-27 Yeda Research And Development Co. Ltd. Peptides for treating Sjogren's syndrome
EP3608615A4 (en) * 2017-04-04 2021-01-20 Nitto Denko Corporation LYOPHILIZED BODY MANUFACTURING PROCESS AND ITS MANUFACTURING DEVICE
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
ES2969958T3 (es) * 2017-11-30 2024-05-23 Cytogel Pharma Llc Formulaciones farmacéuticas analgésicas novedosas y usos de las mismas
CN112143707A (zh) * 2020-09-29 2020-12-29 广东先康达生物科技有限公司 一种治疗自身免疫细胞的免疫细胞及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60184098A (ja) * 1984-03-02 1985-09-19 Suntory Ltd 新規なペプチド及びこれを有効成分とする利尿剤
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5126249A (en) * 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
US6613536B1 (en) * 1995-03-28 2003-09-02 Yeda Research And Development Co. Ltd. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
IL113159A0 (en) * 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US20020054872A1 (en) * 1997-03-20 2002-05-09 Yaakov Naparstek Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus
IL120503A0 (en) * 1997-03-20 1997-07-13 Hadasit Med Res Service Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
SE9802938D0 (sv) * 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
CA2513331A1 (en) * 2003-01-14 2004-08-05 Teva Pharmaceutical Industries Ltd Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
DK1594434T3 (da) * 2003-01-14 2017-01-02 Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus
US7018891B2 (en) * 2003-12-16 2006-03-28 International Business Machines Corporation Ultra-thin Si channel CMOS with improved series resistance

Also Published As

Publication number Publication date
CA2513320C (en) 2018-03-27
EP1594434B1 (en) 2016-09-07
NZ541658A (en) 2008-04-30
EA009123B1 (ru) 2007-10-26
DK1594434T3 (da) 2017-01-02
EP1594434A2 (en) 2005-11-16
IL169574A (en) 2015-08-31
IL169574A0 (en) 2007-07-04
IS7972A (is) 2006-07-15
NO20053773L (no) 2005-10-12
CN1774259B (zh) 2011-12-28
AU2004206842A1 (en) 2004-08-05
BRPI0406745A (pt) 2005-12-20
WO2004064787A3 (en) 2005-12-15
US20050008634A1 (en) 2005-01-13
CR7938A (es) 2006-05-31
JP2011173888A (ja) 2011-09-08
WO2004064787A2 (en) 2004-08-05
KR20050100617A (ko) 2005-10-19
NO20053773D0 (no) 2005-08-08
CA2513320A1 (en) 2004-08-05
EP1594434A4 (en) 2008-09-10
JP2006517540A (ja) 2006-07-27
ECSP055961A (es) 2006-04-19
ZA200506206B (en) 2006-12-27
US20130023485A1 (en) 2013-01-24
US20090169559A1 (en) 2009-07-02
CN1774259A (zh) 2006-05-17
ES2606464T3 (es) 2017-03-24
MXPA05007549A (es) 2006-05-19
JP4817068B2 (ja) 2011-11-16
EA200501131A1 (ru) 2006-04-28

Similar Documents

Publication Publication Date Title
CO5640143A2 (es) Formulaciones parenterales de un peptido para el tratamiento de lupus eritematoso sistematico
JP6034329B2 (ja) 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
US20040185060A1 (en) Immunological enhancement agent comprising N-terminal peptide of p43 as an effective component
JP6987744B2 (ja) 虫刺され過敏症の治療
EP1496926A4 (en) USE OF TRANSTHYRETIN PEPTIDE / PROTEIN FUSIONS FOR INCREASING THE SERUM HALF-LIFE OF PHARMACOLOGICALLY ACTIVE PEPTIDES / PROTEINS
JP2009539349A5 (es)
RU2194054C2 (ru) Синтетические аналоги il-10
JP2010500360A5 (es)
WO2002048183A3 (en) Compositions of peptide crystals
JP2008543878A5 (es)
JP2014521684A5 (es)
JP2010529957A5 (es)
JP2019533722A5 (es)
US20170065670A1 (en) Methods for treating immune mediated neurological diseases
KR101510082B1 (ko) 비만증을 억제하기 위한 백신 및 방법
EP2320924B1 (en) A polypeptide for use in treating dengue virus infections
WO2001043691A3 (en) Fragments and antagonists of heat shock protein 60
DE60323634D1 (de) Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16
RS20050662A (en) Liquid formulations of tumor necrosis factor-binding proteins
EA200501129A1 (ru) Парентеральные композиции пептида для лечения системной красной волчанки
JP2007516701A5 (es)
WO2002007676A3 (en) Compounds having affinity for the granulocyte-colony stimulating factor receptor (g-csfr)
KR20220044947A (ko) 진균 감염의 치료를 위한 조성물 및 방법(compositions and methods for treatment of fungal infections)
JP2004525988A5 (es)
WO2001051512A3 (en) Human and parasite orphan receptor proteins

Legal Events

Date Code Title Description
FC Application refused